Solid tumors · Oncology · 8 drugs · 5 indications
| Drug | Company | Mechanism | Modality | Route | Stage |
|---|---|---|---|---|---|
| puxitatug samrotecan | AZN | HER3-directed (samrotecan payload) | ADC | IV | PHASE3 |
| sonesitatug vedotin | AZN | ROR1-directed (vedotin payload) | ADC | IV | PHASE3 |
| torvutatug samrotecan | AZN | EGFR-directed (samrotecan payload) | ADC | IV | PHASE3 |
| surovatamig | AZN | DLL3 T-cell engager | Bispecific | IV | PHASE3 |
| AZD6234 | AZN | — | Small molecule | ORAL | PHASE2 |
| AZD0120 | AZN | — | CAR-T | IV | PHASE1 |
| DS-3939 | DSNKY | TA-MUC1-directed (DXd payload) | ADC | IV | PHASE1 |
| Enhertu | AZN, DSNKY | HER2-directed (DXd payload) | ADC | IV | APPROVED |